Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: Prognostic relevance of early and late assessment

Leukemia

Volumn 29, Issue 8, 2015, Pages 1648-1655

  Eckert, C ^a   Hagedorn, N ^a   Sramkova, L ^b,c   Mann, G ^d   Panzer Grumayer R ^d   Peters, C ^d   Bourquin, J P ^e   Klingebiel, T ^f   Borkhardt, A ^g   Cario, G ^h   Alten, J ^h   Escherich, G ⁱ   Astrahantseff, K ^a   Seeger, K ^a   Henze, G ^a   Von Stackelberg, A ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g HEINRICH HEINE UNIVERSITY   (Germany)

^h UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁱ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; ADOLESCENT; CANCER STAGING; CLINICAL TRIAL; INDUCTION CHEMOTHERAPY; MORTALITY; MULTICENTER STUDY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PATHOLOGY; PHYSIOLOGIC MONITORING; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RISK FACTOR; SURVIVAL RATE;

ANTINEOPLASTIC AGENT;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MONITORING, PHYSIOLOGIC; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84938969742     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.59     Document Type: Article

References (38)

1. Borgmann A, von Stackelberg A, Hartmann R, Ebell W, Klingebiel T, Peters C et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. Blood 2003; 101: 3835-3839.
2. Gaynon PS. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol 2005; 131: 579-587.
3. Nguyen K, Devidas M, Cheng SC, La M, Raetz EA, Carroll WL et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia 2008; 22: 2142-2150.
4. Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet 2010; 376: 2009-2017.
5. Bailey LC, Lange BJ, Rheingold SR, Bunin NJ. Bone-marrow relapse in paediatric acute lymphoblastic leukaemia. Lancet Oncol 2008; 9: 873-883.
6. Henze G, Stackelberg A, Eckert C. ALL-REZ BFM-the consecutive trials for children with relapsed acute lymphoblastic leukemia. Klinische Padiatrie 2013; 225: S73-S78.
7. Mehta PA, Davies SM. Allogeneic transplantation for childhood ALL. Bone Marrow Transplant 2008; 41: 133-139.
8. Einsiedel HG, von Stackelberg A, Hartmann R, Fengler R, Schrappe M, Janka-Schaub G et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87. J Clin Oncol 2005; 23: 7942-7950.
9. Leung W, Campana D, Yang J, Pei D, Coustan-Smith E, Gan K et al. High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood 2011; 118: 223-230.
10. Tallen G, Ratei R, Mann G, Kaspers G, Niggli F, Karachunsky A et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol 2010; 28: 2339-2347.
11. Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: The ALL-REZ BFM Study Group. J Clin Oncol 2009; 27: 377-384.
12. Leung W, Pui CH, Coustan-Smith E, Yang J, Pei D, Gan K et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood 2012; 120: 468-472.
13. Paganin M, Zecca M, Fabbri G, Polato K, Biondi A, Rizzari C et al. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia. Leukemia 2008; 22: 2193-2200.
14. Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ et al. Rein-duction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study. J Clin Oncol 2008; 26: 3971-3978.
15. Bene MC, Bernier M, Casasnovas RO, Castoldi G, Knapp W, Lanza F et al. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). Blood 1998; 92: 596-599.
16. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995; 9: 1783-1786.
17. Borowitz M, Bene M-C, Harris N, Porwit A, Matutes E. Acute leukemias of ambiguous lineage. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC 2008, 149-155.
18. Henze G Charite University Berlin, Germany. ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia. In.
19. ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000 (cited 18 July 2009) available from http://clinicaltrialsgov/ct2/show/NCT00114348, NLM identifier: NCT00114348 2005.
20. Schrauder A, von Stackelberg A, Schrappe M, Cornish J, Peters C. Allogeneic hematopoietic SCT in children with ALL: current concepts of ongoing prospective SCT trials. Bone Marrow Transplant 2008; 41: S71-S74.
21. Eckert C, von Stackelberg A, Seeger K, Groeneveld TW, Peters C, Klingebiel T et al. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia-long-term results of trial ALL-REZ BFM P95/96. Eur J Cancer 2013; 49: 1346-1355.
22. Langerak AW, Szczepanski T, van der Burg M, Wolvers-Tettero IL, van Dongen JJ. Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations. Leukemia 1997; 11: 2192-2199.
23. Pongers-Willemse MJ, Seriu T, Stolz F, d'Aniello E, Gameiro P, Pisa P et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 110-118.
24. Szczepanski T, Pongers-Willemse MJ, Langerak AW, Harts WA, Wijkhuijs AJ, van Wering ER et al. Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant DH6-19 and DH7-27 gene usage, can result in complete V-D-J rearrangements, and are rare in T-cell receptor alpha beta lineage. Blood 1999; 93: 4079-4085.
25. Szczepanski T, van der Velden VH, Hoogeveen PG, de Bie M, Jacobs DC, van Wering ER et al. Vdelta2-Jalpha rearrangements are frequent in precursor-B-acute lymphoblastic leukemia but rare in normal lymphoid cells. Blood 2004; 103: 3798-3804.
26. Eckert C, Landt O. Real-time PCR to detect minimal residual disease in childhood ALL. Methods Mol Med 2004; 91: 175-182.
27. van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007; 21: 604-611.
28. Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet 2002; 359: 1686-1689.
29. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
30. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. Wiley: New York, NY, USA, 1980, 168-189.
31. Goulden N, Bader P, Van Der Velden V, Moppett J, Schilham M, Masden HO et al. Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia. Br J Haematol 2003; 122: 24-29.
32. Knechtli CJ, Goulden NJ, Hancock JP, Grandage VL, Harris EL, Garland RJ et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 1998; 92: 4072-4079.
33. Krejci O, van der Velden VH, Bader P, Kreyenberg H, Goulden N, Hancock J et al. Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group. Bone Marrow Transplant 2003; 32: 849-851.
34. Sramkova L, Muzikova K, Fronkova E, Krejci O, Sedlacek P, Formankova R et al. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2007; 48: 93-100.
35. Balduzzi A, Di Maio L, Silvestri D, Songia S, Bonanomi S, Rovelli A et al. Minimal residual disease before and after transplantation for childhood acute lympho-blastic leukaemia: is there any room for intervention? Br J Haematol 2014; 164: 396-408.
36. Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011; 118: 4817-4828.
37. Handgretinger R, Zugmaier G, Henze G, Kreyenberg H, Lang P, von Stackelberg A. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia 2011; 25: 181-184.
38. Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS et al. Immuno-pharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012; 119: 6226-6233.